ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
120 announcements with these filters
MedPlus reported Q4 FY26 consolidated revenue of INR 18,644 million with a 5.8% EBITDA margin. Strategy shifts toward a franchisee model for faster, capital-efficient expansion.
MedPlus subsidiary Optival Health Solutions received drug license suspension orders for two Karnataka stores. The temporary closures will result in a combined ₹0.03 Crore revenue loss.
Medplus delivered strong revenue growth while pivoting toward a franchise-led expansion model to optimize capital allocation. Management maintains a confident tone despite store closures and fluctuating private label contributions.
MedPlus Health Services subsidiary received two drug license suspension orders for stores in Telangana and Karnataka. The suspensions cause a ₹0.05 Crore total potential revenue loss.
Medplus Health Services approved the appointment of two independent directors and re-appointed Gangadi Madhukar Reddy. These leadership changes aim to strengthen corporate governance and strategic oversight.
MedPlus Health Services reports the resignation of Company Secretary Monoj Kumar Srivastava effective May 20, 2026. He departs to pursue external professional growth opportunities.
MedPlus FY26 revenue reached ₹68,925m, up 12.3% YoY. Strategy focuses on cluster-based expansion with 5,330 stores and increasing private label share.
MedPlus Health Services appointed two new independent directors and re-appointed its Managing Director for five-year terms. These leadership changes aim to strengthen corporate governance and stability.
MedPlus Health Services allotted 82,419 equity shares following ESOP exercises. Total paid-up capital increased to ₹24.02 Crore, reflecting employee benefit program execution.
Medplus Health Services Ltd reported revenue from operations of ₹1,864 Cr (+23.5% YoY) and net profit of ₹64 Cr (+24.8% YoY) for Q4 FY26.
MedPlus Health Services Limited reported audited financial results for FY2026. Consolidated net profit reached ₹219.61 Crore on total revenue of ₹6,963.79 Crore.
MedPlus subsidiary Optival Health Solutions received a three-day drug license suspension for a Telangana store. The event carries a potential ₹0.02 Crore revenue impact.
MedPlus subsidiary Optival Health Solutions received a two-day drug license suspension for its Karnataka store. The temporary closure results in a ₹0.01 Crore revenue loss.
MedPlus subsidiary received drug license suspension orders for two Karnataka stores, totaling ₹0.03 Crore in potential revenue loss. Operations will halt temporarily at affected locations.
MedPlus subsidiary Optival Health Solutions received a one-day drug license suspension for its Delhi store. The impact is minimal with ₹0.00 Crore estimated revenue loss.
MedPlus subsidiary Optival Health received one-day drug license suspensions for two stores in Telangana and Karnataka. The temporary closures carry a total potential revenue loss of ₹0.24 lacs.
MedPlus subsidiary Optival Health Solutions received a five-day drug license suspension for its Nashik store from Maharashtra regulatory authorities. The suspension, due to alleged Rule 65 violations, results in a potential revenue loss of ₹0.75 lacs (₹0.01 Crore).
MedPlus subsidiary Optival Health Solutions received a 65-day drug license suspension order for its Durg, Chhattisgarh store. The suspension, issued by the Assistant Drugs Controller, results in a potential revenue loss of ₹0.16 Crore.
Medplus Health Services Limited has rescheduled its Board meeting to May 20, 2026, from the originally planned May 29, 2026. The meeting will consider the audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until May 22, 2026.
MedPlus Health Services Limited has rescheduled its board meeting to May 20, 2026. The board will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for designated persons remains closed until May 22, 2026.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a three-day drug license suspension for a store in Ganeshpeth, Hubli. The suspension, issued by Karnataka's Drugs Control Administration, involves an estimated potential revenue loss of ₹0.01 Crore. The company is complying with the order issued under the Drugs and Cosmetics Act.
MedPlus Health Services Limited has received two stay orders against a previously disclosed suspension from authorities in Pune, Maharashtra. This legal update follows earlier submissions made in February and March 2026. The stay orders allow for the resumption of business operations in the affected region, providing regulatory relief for the company.
MedPlus subsidiary Optival Health Solutions received a five-day drug license suspension for its Jayanagar, Karnataka store. The suspension, effective from April 21, 2026, results in a potential revenue loss of ₹0.05 Crore.
MedPlus Health Services Limited's subsidiary received suspension orders for drug licenses at two stores in Andhra Pradesh and Telangana. The suspensions, lasting seven and two days respectively, carry a combined potential revenue loss of approximately ₹0.01 Crore. Operations at these specific locations will be temporarily disrupted due to regulatory non-compliance under the Drugs and Cosmetics Rules.
MedPlus Health subsidiary Optival Health Solutions received suspension orders for drug licenses at two Karnataka stores. The suspensions, lasting four and five days respectively, involve a combined potential revenue loss of ₹0.05 Crore. The action was taken by the Bangalore Drugs Control Administration under the Drugs and Cosmetics Act.
MedPlus Health Services' subsidiary, Optival Health Solutions, received drug license suspension orders for two stores in Andhra Pradesh and Odisha. The suspensions, lasting seven and two days respectively, carry a combined potential revenue loss of ₹0.07 Crore. The actions were taken due to alleged violations of the Drugs and Cosmetics Rules, 1945.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a five-day drug license suspension for its Odisha store. The suspension, effective from April 10, 2026, involves a potential revenue loss of ₹0.04 Crore.
MedPlus subsidiary Optival Health Solutions received a two-day drug license suspension order for a store in Jadcherla, Telangana. The suspension, effective from April 8, 2026, carries a negligible estimated revenue loss of ₹0.28 lacs (approximately ₹0.00 Crore) and follows alleged violations of the Drugs and Cosmetics Act, 1940.
MedPlus Health Services Limited submitted its quarterly compliance certificate under SEBI (DP) Regulations for the period ended March 31, 2026. The certificate, issued by KFin Technologies, confirms that security details for dematerialized/rematerialized shares were furnished to stock exchanges.
MedPlus Health Services' subsidiary, Optical Health Solutions, received a two-day drug license suspension for its Jangaon, Telangana store. Issued by the Drugs Control Administration for Rule 65 violations, the suspension carries a negligible estimated revenue impact of ₹0.00 Crore (Rs 0.16 lacs).